IVISense™ Vascular NP (AngioSPARK®) is a fluorescent nanoparticle probe with a long pharmacokinetic profile for imaging vascularity, vascular leak, blood-brain-barrier compromise, and vascular cell fluid-phase pinocytosis.
PerkinElmer's IVISense Vascular NP fluorescent nanoparticle probes are available in 680 and 750 nm wavelengths ideal for multiplexing with other probes.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense Vascular NP 750 is a highly fluorescent near-infrared nanoparticle probe specifically designed for in vivo imaging. IVISense Vascular NP 750 contains an iron oxide core that is coated to specifically produce a functionalized biocompatible probe comprised of a pegylated fluorescent nanoparticle that remains localized in the vasculature for extended periods of time and enables imaging of blood vessels, angiogenesis, blood-brain-barrier compromise, and vascular cell fluid-phase pinocytotic function. IVISense Vascular NP 750 fluorescent nanoparticle probe can also be used at later time points (>12 hours) to image vascular leak in tissue site of inflammation and cancer. IVISense Vascular NP 750 can be imaged within the interstitium for up to 24 hours post tail vein injection.
Benefits of IVISense Vascular NP fluorescent nanoparticles
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Vascular disease, Angiogenesis, Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (5 doses)|
|Wave Length||750 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This selector guide for IVISense™ fluorescent probes is a powerful tool to help advance your oncology research. By matching probe properties to specific biology and biomarker characteristics, you can better understand how imaging and quantification of early biological changes associated with disease development, therapeutic efficacy, and drug-induced tissue changes can be realized.
NanoSPARKS™ are a new family of highly fluorescent near infrared nanoparticles specifically designed for in vivo imaging. NanoSPARKS contain an iron oxide core that is coated to specifically produce a functionalized biocompatible product. AngioSPARK® 750 comprises pegylated fluorescent nanoparticles that remain localized in the vasculature for extended periods of time and enable imaging of blood vessels and angiogenesis.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.